{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:06:16Z","timestamp":1760267176571,"version":"3.40.3"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.tips.2012.06.001","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T04:17:05Z","timestamp":1340684225000},"page":"474-481","source":"Crossref","is-referenced-by-count":16,"title":["Complex and defined biostructures with the dock-and-lock method"],"prefix":"10.1016","volume":"33","author":[{"given":"Edmund A.","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hsing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2012.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nbt1127","article-title":"Engineering novel binding proteins from nonimmunoglobulin domains","volume":"23","author":"Binz","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2012.06.001_bib0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.copbio.2005.06.005","article-title":"Engineered proteins as specific binding reagents","volume":"16","author":"Binz","year":"2005","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.tips.2012.06.001_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tibtech.2010.03.007","article-title":"Multivalent antibodies: when design surpasses evolution","volume":"28","author":"Cuesta","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tips.2012.06.001_bib0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tibtech.2005.07.007","article-title":"Artificial, non-antibody binding proteins for pharmaceutical and industrial applications","volume":"23","author":"Hey","year":"2005","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tips.2012.06.001_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1110\/ps.051817606","article-title":"A new generation of protein display scaffolds for molecular recognition","volume":"15","author":"Hosse","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.tips.2012.06.001_bib0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4049\/jimmunol.166.1.559","article-title":"A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway","volume":"166","author":"Kishore","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2012.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4049\/jimmunol.148.5.1547","article-title":"Formation of a bispecific antibody by the use of leucine zippers","volume":"148","author":"Kostelny","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2012.06.001_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/jmbi.1994.0062","article-title":"Tetravalent miniantibodies with high avidity assembling in Escherichia coli","volume":"246","author":"Pack","year":"1995","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2012.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1073\/pnas.94.5.1663","article-title":"\u2018Peptabody\u2019: a new type of high avidity binding protein","volume":"94","author":"Terskikh","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2012.06.001_bib0050","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.1074\/jbc.M011669200","article-title":"Tumor targeting of mono-, di-, and tetravalent anti-p185 (HER-2) miniantibodies multimerized by self-associating peptides","volume":"276","author":"Willuda","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2012.06.001_bib0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/bc2004999","article-title":"The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures","volume":"23","author":"Rossi","year":"2012","journal-title":"Bioconjug. Chem"},{"key":"10.1016\/j.tips.2012.06.001_bib0060","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1073\/pnas.0600982103","article-title":"Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting","volume":"103","author":"Rossi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2012.06.001_bib0065","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.febslet.2005.03.089","article-title":"Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract","volume":"579","author":"Baillie","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tips.2012.06.001_bib0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrm1527","article-title":"AKAP signaling complexes: focal points in space and time","volume":"5","author":"Wong","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tips.2012.06.001_bib0075","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1016\/S0021-9258(18)98665-5","article-title":"Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif","volume":"266","author":"Carr","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2012.06.001_bib0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0962-8924(99)01558-5","article-title":"AKAPs: from structure to function","volume":"9","author":"Colledge","year":"1999","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.tips.2012.06.001_bib0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/6663","article-title":"The molecular basis for protein kinase A anchoring revealed by solution NMR","volume":"6","author":"Newlon","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.tips.2012.06.001_bib0090","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/emboj\/20.7.1651","article-title":"A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes","volume":"20","author":"Newlon","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2012.06.001_bib0095","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1073\/pnas.0330734100","article-title":"Bioinformatic design of A-kinase anchoring protein in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring","volume":"100","author":"Alto","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2012.06.001_bib0100","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/bc060037u","article-title":"Self-assembled \u2018dock and lock\u2019 system for linking payloads to targeting proteins","volume":"17","author":"Backer","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.tips.2012.06.001_bib0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nmeth729","article-title":"Using protein\u2013DNA chimeras to detect and count small numbers of molecules","volume":"2","author":"Burbulis","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tips.2012.06.001_bib0110","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/nbt916","article-title":"Design of multivalent complexes using the barnase\u00b7barstar module","volume":"21","author":"Deyev","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2012.06.001_bib0115","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1073\/pnas.072685299","article-title":"Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands","volume":"99","author":"Hodneland","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2012.06.001_bib0120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0022-3565(24)29633-6","article-title":"Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity","volume":"297","author":"Pepinsky","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2012.06.001_bib0125","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1016\/j.bmcl.2004.09.083","article-title":"Improving the intein-mediated, site-specific protein biotinylation strategies both in vitro and in vivo","volume":"14","author":"Tan","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2012.06.001_bib0130","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.1158\/0008-5472.CAN-08-2033","article-title":"Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics","volume":"68","author":"Rossi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0135","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","article-title":"Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20\/CD22 antibodies in lymphoma","volume":"113","author":"Rossi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0140","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2009-06-228890","article-title":"CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas","volume":"114","author":"Rossi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0145","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1158\/0008-5472.CAN-10-2126","article-title":"A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells","volume":"70","author":"Rossi","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0150","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1021\/bc9001773","article-title":"A new method to produce monoPEGylated dimeric cytokines shown with human interferon-alpha2b","volume":"20","author":"Chang","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.tips.2012.06.001_bib0155","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1158\/0008-5472.CAN-05-0420","article-title":"Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen)","volume":"65","author":"Blumenthal","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0160","first-page":"3886S","article-title":"Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy","volume":"9","author":"Rossi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2009.12.002","article-title":"Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy","volume":"40","author":"Sharkey","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0170","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-03-343145","article-title":"Preclinical studies on targeted delivery of multiple IFN\u03b12b to HLA-DR in diverse hematologic cancers","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0175","unstructured":"Chang, C-H. and Goldenberg, D.M. IBC Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA, US2011\/012346A1"},{"key":"10.1016\/j.tips.2012.06.001_bib0180","unstructured":"Chang, C-H. et al. IBC Pharmaceuticals, Inc. and Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity, US2011\/0274704A1"},{"key":"10.1016\/j.tips.2012.06.001_bib0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/COH.0b013e32832498d8","article-title":"The fusion inhibitor enfuvirtide in recent antiretroviral strategies","volume":"4","author":"Makinson","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2012.06.001_bib0190","unstructured":"Chang, C-H. et al. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PLoS ONE (in press)"},{"key":"10.1016\/j.tips.2012.06.001_bib0195","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2967\/jnumed.108.060418","article-title":"A novel method of 18F radiolabeling for PET","volume":"50","author":"McBride","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0200","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2967\/jnumed.110.079376","article-title":"Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice","volume":"51","author":"Schoffelen","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1148\/radiol.2462070229","article-title":"Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model","volume":"246","author":"Sharkey","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.tips.2012.06.001_bib0210","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1158\/0008-5472.CAN-08-0232","article-title":"A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma","volume":"68","author":"Gold","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.107.046185","article-title":"Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting","volume":"49","author":"Goldenberg","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0220","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2967\/jnumed.109.067686","article-title":"Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine","volume":"50","author":"Karacay","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0225","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2967\/jnumed.110.083568","article-title":"Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga","volume":"52","author":"Karacay","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1535-7163.MCT-09-0862","article-title":"Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts","volume":"9","author":"Schoffelen","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2012.06.001_bib0235","doi-asserted-by":"crossref","first-page":"5577s","DOI":"10.1158\/1078-0432.CCR-07-1087","article-title":"Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update","volume":"13","author":"Sharkey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0240","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1158\/0008-5472.CAN-08-0037","article-title":"Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody","volume":"68","author":"Sharkey","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0245","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.108.058602","article-title":"Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma","volume":"50","author":"Sharkey","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2012.06.001_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cbr.2009.0690","article-title":"Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies","volume":"25","author":"Sharkey","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.tips.2012.06.001_bib0255","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2012.06.001_bib0260","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tips.2012.06.001_bib0265","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood-2010-03-276857","article-title":"Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20\/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0270","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2011-09-381988","article-title":"Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20\/CD74 bispecific antibodies in mantle cell and other lymphomas","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0275","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","article-title":"Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma","volume":"115","author":"Xuan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tips.2012.06.001_bib0280","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways","volume":"115","author":"Stein","year":"2010","journal-title":"Blood"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614712000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614712000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:48:55Z","timestamp":1743612535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614712000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0165614712000892"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2012.06.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"type":"print","value":"0165-6147"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}